RECENT Healthcare RESEARCH
GlaxoSmithKline (GSK) is set to release its earnings on October 28, 2015. Analysts estimate an EPS of 0.39 pounds for 3Q15.
As of October 14, 2015, the iShares U.S. Healthcare Providers ETF (IHF) gave a return of -1%, while the SPDR S&P 500 ETF (SPY) gave a return of -0.5%.
Johnson & Johnson (JNJ) has a market cap of $264.3 billion. Its YTD price movement was stable. It was in a trading range until the earnings report in 3Q15.
On October 12, 2015, Eli Lilly and Company announced its decision to terminate the cardiovascular drug Evacetrapib during its phase 3 trial.
Ultragenyx Pharmaceutical (RARE) fell by 8.2% due to profit-booking. It had a high trading volume of ~700,000 shares. The stock closed at $86.99.
On October 12, the iShares US Medical Devices ETF rose by 0.15% to close at $115.35. The broader market SPDR S&P 500 ETF (SPY) rose by 0.09%.
Dyax gained 21.3% for the week ended October 9. It has been on an upward trend since it received positive results for EU orphan medical product designation for DX-2930.
Aristada was approved by the FDA and is projected to account for 10% to 30% of the LAI atypical antipsychotic market for schizophrenia patients in the US.
The SPDR S&P Biotech ETF (XBI) had a mixed day on October 8, 2015. Of the 101 holdings, 32 stocks ended up in green, and 69 stocks ended up in red. But overall, XBI fell 1.0% for the day.
The tug-of-war between the bulls and bears continues in the biotech sector. The biotech stocks rose again and regained some of their lost ground on October 6.
On October 2, 2015, the U.S. Food and Drug Administration approved Merck’s Keytruda to treat patients suffering with advanced non-small cell lung cancer.
Illumina (ILMN) fell by 10.6% on Tuesday, October 6. It announced an estimated third-quarter revenue of ~$550 million. Illumina closed at $145.81.
The Health Care Select Sector SPDR ETF (XLV) offers a range of investment opportunities in different sectors of the biotech industry.
The iShares Nasdaq Biotechnology ETF (IBB) gained 1.71% for the week while the broader market SPDR S&P 500 ETF (SPY) gained 1.1% for the same period.
XLV outperformed the broader market representative SPDR S&P 50 ETF on October 1, 2015. SPY rose by 0.26% , compared with XLV’s 1.01%.
Perrigo is a leading healthcare supplier. It develops and distributes over-the-counter prescription pharmaceutical and nutritional products.
Novo Nordisk (NVO) is a leader in diabetes care with 90 years of experience coupled with a strong workforce of 39,700 in 75 countries around the world.
Last week was an unforgettable week for biotech stocks. It began on a bad note after Hillary Clinton commented on price controls for the specialty drug market, which created panic and triggered a sell-off.
Clovis Oncology (CLVS) gained 9.88%, as investors were positive about the company’s presentation at the Morgan Stanley global healthcare conference.
An overview of Illumina, a leading biotechnology company, which holds a market capitalization of $27.5 billion.